AstraZeneca vaccine effective against Covid-19 variants identified in India

Reuters June 23 | Updated on June 23, 2021

Company cites study by Oxford University

AstraZeneca Plc’s Covid-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, the company said on Tuesday, citing a study.

The study by the Oxford University investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralise the Delta and Kappa variants, the statement said. Last week, an analysis by Public Health England (PHE)showed that vaccines made by Pfizer Inc and AstraZeneca offer high protection of more than 90 per cent against hospitalisation from the Delta variant.

Working with AstraZeneca, SII, Indian govt to restart Covid-19 vaccine shipments: WHO Official

The latest Oxford study results are built on the recent analysis by PHE, the company said.

AstraZeneca says antibody treatment failed in preventing Covid-19 in exposed patients

The Delta variant is becoming the globally dominant version of the disease, the World Health Organization’s chief scientist said on Friday.

Published on June 23, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor